Overview

  • Product nameAnti-SHP2 antibody
    See all SHP2 primary antibodies
  • Description
    Rabbit polyclonal to SHP2
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Rat
    Predicted to work with: Mouse, Human
  • Immunogen

    Synthetic peptide derived from residues 250 - 350 of Human SHP2.

    .

  • Positive control
    • This antibody gave a positive signal in the following whole cell lysate: Jurkat.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab10555 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1 - 2 µg/ml. Predicted molecular weight: 68 kDa. Can be blocked with SHP2 peptide

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionActs downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus.
    • Tissue specificityWidely expressed, with highest levels in heart, brain, and skeletal muscle.
    • Involvement in diseaseDefects in PTPN11 are the cause of LEOPARD syndrome type 1 (LEOPARD1) [MIM:151100]. It is an autosomal dominant disorder allelic with Noonan syndrome. The acronym LEOPARD stands for lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and deafness.
      Defects in PTPN11 are the cause of Noonan syndrome type 1 (NS1) [MIM:163950]. Noonan syndrome (NS) is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. Some patients with Noonan syndrome type 1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villomoduolar synovitis (PVNS) when occurring in the jaw or joints. Note=Mutations in PTPN11 account for more than 50% of the cases. Rarely, NS is associated with juvenile myelomonocytic leukemia (JMML). NS1 inheritance is autosomal dominant.
      Defects in PTPN11 are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. It is characterized by leukocytosis with tissue infiltration and in vitro hypersensitivity of myeloid progenitors to granulocyte-macrophage colony stimulating factor.
      Defects in PTPN11 are a cause of metachondromatosis (MC) [MIM:156250]. It is a skeletal disorder with radiologic fetarures of both multiple exostoses and Ollier disease, characterized by the presence of multiple enchondromas and osteochondroma-like lesions.
    • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Non-receptor class 2 subfamily.
      Contains 2 SH2 domains.
      Contains 1 tyrosine-protein phosphatase domain.
    • DomainThe SH2 domains repress phosphatase activity. Binding of these domains to phosphotyrosine-containing proteins relieves this auto-inhibition, possibly by inducing a conformational change in the enzyme.
    • Post-translational
      modifications
      Phosphorylated on Tyr-546 and Tyr-584 upon receptor protein tyrosine kinase activation; which creates a binding site for GRB2 and other SH2-containing proteins.
    • Cellular localizationCytoplasm.
    • Information by UniProt
    • Database links
    • Alternative names
      • BPTP3 antibody
      • CFC antibody
      • JMML antibody
      • METCDS antibody
      • MGC14433 antibody
      • NS1 antibody
      • OTTHUMP00000166107 antibody
      • OTTHUMP00000166108 antibody
      • Protein tyrosine phosphatase 2 antibody
      • Protein tyrosine phosphatase 2C antibody
      • Protein tyrosine phosphatase non receptor type 11 antibody
      • Protein-tyrosine phosphatase 1D antibody
      • Protein-tyrosine phosphatase 2C antibody
      • PTN11_HUMAN antibody
      • PTP-1D antibody
      • PTP-2C antibody
      • PTP1D antibody
      • PTP2C antibody
      • PTPN11 antibody
      • SAP2 antibody
      • SH-PTP2 antibody
      • SH-PTP3 antibody
      • SH2 domain containing protein tyrosine phosphatase 2 antibody
      • SHP 2 antibody
      • SHP-2 antibody
      • Shp2 antibody
      • SHPTP2 antibody
      • SHPTP3 antibody
      • Syp antibody
      • Tyrosine-protein phosphatase non-receptor type 11 antibody
      see all

    Anti-SHP2 antibody images



    • Predicted band size : 68 kDa

      Lane 1: Wild-type HAP1 cell lysate (20 µg)
      Lane 2: SHP2 knockout HAP1 cell lysate (20 µg)
      Lane 3: A431 cell lysate (20 µg)
      Lane 4: Jurkat cell lysate (20 µg)  
      Lanes 1 to 4: Merged signal (red and green). Green - ab10555 observed at 70 kDa. Red - loading control, ab8245, observed at 37 kDa.
      ab10555 was shown to recognize SHP2 when SHP2 knockout samples were used, along with additional cross-reactive bands. Wild-type and SHP2 knockout samples were subjected to SDS-PAGE. ab10555 and ab8245 (loading control to GAPDH) were both diluted at 1 µg/ml and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.



    • Performed under reducing conditions.

      Predicted band size : 68 kDa

      Jurkat cell lysates (lanes 1 and 2) were probed with ab10555 at 1/500.  This antibody recognises SHP2 at 68 kDa.  The lower molecular weight band may represent a variant or differences in the post-translational modification of the protein.
      M: marker
      lane 1: ab10555
      lane 2: ab10555 + blocking peptide 

      M=Marker

    References for Anti-SHP2 antibody (ab10555)

    This product has been referenced in:
    • Tsang YH  et al. Novel Functions of the Phosphatase SHP2 in the DNA Replication and Damage Checkpoints. PLoS One 7:e49943 (2012). WB . Read more (PubMed: 23189174) »
    • Banes-Berceli AK  et al. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 293:H1291-9 (2007). WB ; Rat . Read more (PubMed: 17526654) »

    See all 3 Publications for this product

    Product Wall

    Application Western blot
    Sample Human Cell lysate - whole cell (PBMC)
    Specification PBMC
    Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 1%
    Username

    Abcam user community

    Verified customer

    Submitted Aug 05 2005

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"